Leucemia Mieloide Crónica (LMC) Juvenil. A Propósito de un Caso
Autores
Claudio Monge, Esteban Castro, Juan José Rivas-Mejías, Lilliana Calvo, Luisa Vindas-Angulo, Marianela Solano, María Fernanda Sánchez
Resumen
La leucemia Mieloide Crónica (LMC) es una neoplasia mieloproliferativa crónica, caracterizada por un gen de fusión t(9,22). El curso normal de la enfermedad consta de 3 fases: crónica, acelerada y blástica. En su gran mayoría los pacientes son diagnosticados en fase crónica y por un hallazgo incidental. Es común en pacientes mayores de 60 años, y poco frecuentes en niños y adolescentes, de ahí la importancia del reporte de este caso. Caso clínico: Paciente diagnosticado con LMC que progresó a fase acelerada, debido a falla terapéutica a primera línea de tratamiento con imatibinib y segunda línea con nilotinib. Dicha falla se justifica por poca adherencia al tratamiento. La importancia de este reporte recae en la baja incidencia de casos de LMC juvenil y las diferencias reportadas en la literatura en cuanto a una progresión clínica más agresiva.
Palabras clave
Leucemia Mielógena Crónica BCR-ABL Positiva, Cromosoma Filadelfia, Mesilato de ImatinibAbstract
Chronic myeloid leukemia (CML) is a chronic myeloproliferative neoplasm, characterized by a fusion gene t(9,22). The normal course of the disease consists in 3 phases: chronic, accelerated and blastic. The vast majority of patients are diagnosed in the chronic phase by an incidental finding. It is common in patients older than 60 years, and infrequent in children and adolescents, hence the importance of this case report. Clinical case: Patient with a diagnosis of CML that progresses to an accelerated phase, due to therapeutic failure in the first line of treatment with imatibinib and second line with nilotinib. This failure is justified by poor adherence to treatment. This report is important due to the low incidence of cases of juvenile CML and the differences reported in the literature, since it has a more aggressive clinical progression than in adults.
Key words
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Philadelphia Chromosome Positive, Imatinib MesylateTexto completo
Referencias
Referencias
1. Apperley JF. Chronic myeloid leukaemia. Lancet. 2017;385(9976):1447–59.
2. Xu W, Chen B, Tong X. Chronic myeloid leukemia patient with co-occurrence of BCR - ABL junction and JAK2 V617F mutation. 2014;87–90.
3. Apperley JF. Chronic myeloid leukaemia. Lancet [Internet]. 2015;385(9976):1447–
59. Available from: http://dx.doi.org/10.1016/S0140-6736(13)62120-0
4. Liesveld J LM. Chronic Myelogenous Leukemia and Related Disorders. In: Kaushansky K, Prchal J, Press O, Lichtman M, Levi M, Burns L CM, editor. Williams Hematology 9th edition. New York: McGraw-Hill Education; 2016. p. 1437–90.
5. Arber DA, Orazi A, Hasserjian R, Borowitz MJ, Beau MM Le, Bloomfield CD, et al. The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia. 2016;127(20):2391–406.
6. Vardiman JW, Melo JV, Baccarani M, Radich JP KH. Chronic myeloid leukaemia, BCR-ABL1 - positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA,
Stein H et al, editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4ta edición. Lyon: Internacional Agency for Research on Cancer; 2017. p. 29–59.
7. Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Perspectives Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. 2016;127(4):392–400.
8. Alikian M, Peter R, Apperley JF, Foroni L. Biomolecular Detection and Quantification Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomol Detect Quantif [Internet]. 2017;11:4–20. Available from: http://dx.doi.org/10.1016/j.bdq.2017.01.001
9. Ross DM, Arthur C, Burbury K, Ko BS, Mills AK, Shortt J, et al. Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors. Intern Med J [Internet]. 2018 Feb;48:5–13. Available from: http://doi.wiley.com/10.1111/imj.13716
10. Varela-Briceño C, Rodriguez-Pineda M, Jimenez-Morales F, Richmond-, Navarro J, Granado-Barrero A, et al. Situación actual de la leucemia mieloide crónica en Costa Rica. 2018;21–6.
11. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. Review Article European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013. 2017;122(6):872–85.
12. Jc T, Wood J, Prostate FD, Castagnetti F, Gugliotta G, Baccarani M, et al. Differences among young adults , adults and elderly. 2014;
13. Lee JW, Chung NG. The treatment of pediatric chronic myelogenous leukemia in the imatinib era. 2011;54(3):111–6.
14. Gugliotta G, Castagnetti F. First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia : Current and Emerging Strategies. 2014;627–43.
15. Seer Pediatric. Cancer Incidence and Survival among Children and Adolescents : United States SEER Program 1975-1995. 1995;
16. Krumbholz M, Karl M, Tauer JT, Thiede C, Rascher W, Suttorp M, et al. Genomic BCR - ABL1 Breakpoints in Pediatric Chronic Myeloid Leukemia.
2012;000(July):1–9.
17. Druker B, Sawyers C, Kantarjian H. ACTIVITY OF A SPECIFIC INHIBITOR OF THE BCR-ABL TYROSINE KINASE IN THE BLAST CRISIS OF CHRONIC
MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA WITH THE PHILADELPHIA CHROMOSOME. Ne w E n g l a nd Jo u r n a l o f Me d ic i ne. 2001;344(14):1038–42.
18. Thompson PA, Kantarjian H, Cortes JE. HHS Public Access. 2017;90(10):1440–54.